Literature DB >> 30936219

Combined MAPK Pathway and HDAC Inhibition Breaks Melanoma.

David B Lombard1,2, Tomasz Cierpicki1, Jolanta Grembecka1.   

Abstract

In this issue, Maertens and colleagues demonstrate that HDAC3 inhibition potentiates the effects of MAPK pathway inhibitors in melanoma, including difficult-to-treat NRAS- and NF1-driven tumors, with MGMT expression serving as a biomarker for responsiveness to the BRAF/MEK/HDAC inhibitor combination. Mechanistically, this triple cocktail suppresses expression of genes involved in DNA repair, leading to enhanced killing of melanoma cells.See related article by Maertens et al., p. 526. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30936219      PMCID： PMC6446927          DOI： 10.1158/2159-8290.CD-19-0069

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 2.  How cells ensure correct repair of DNA double-strand breaks.

Authors:  Joonyoung Her; Samuel F Bunting
Journal:  J Biol Chem       Date:  2018-02-05       Impact factor: 5.157

Review 3.  Targeted agents and immunotherapies: optimizing outcomes in melanoma.

Authors:  Jason J Luke; Keith T Flaherty; Antoni Ribas; Georgina V Long
Journal:  Nat Rev Clin Oncol       Date:  2017-04-04       Impact factor: 66.675

4.  An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.

Authors:  Liqin Wang; Rodrigo Leite de Oliveira; Sanne Huijberts; Evert Bosdriesz; Nora Pencheva; Diede Brunen; Astrid Bosma; Ji-Ying Song; John Zevenhoven; G Tjitske Los-de Vries; Hugo Horlings; Bastiaan Nuijen; Jos H Beijnen; Jan H M Schellens; Rene Bernards
Journal:  Cell       Date:  2018-05-10       Impact factor: 41.582

5.  MGMT gene silencing and benefit from temozolomide in glioblastoma.

Authors:  Monika E Hegi; Annie-Claire Diserens; Thierry Gorlia; Marie-France Hamou; Nicolas de Tribolet; Michael Weller; Johan M Kros; Johannes A Hainfellner; Warren Mason; Luigi Mariani; Jacoline E C Bromberg; Peter Hau; René O Mirimanoff; J Gregory Cairncross; Robert C Janzer; Roger Stupp
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  MAPK Pathway Suppression Unmasks Latent DNA Repair Defects and Confers a Chemical Synthetic Vulnerability in BRAF-, NRAS-, and NF1-Mutant Melanomas.

Authors:  Ophélia Maertens; Ryan Kuzmickas; Haley E Manchester; Chloe E Emerson; Alessandra G Gavin; Caroline J Guild; Terence C Wong; Thomas De Raedt; Christian Bowman-Colin; Elodie Hatchi; Levi A Garraway; Keith T Flaherty; Shailja Pathania; Stephen J Elledge; Karen Cichowski
Journal:  Cancer Discov       Date:  2019-02-01       Impact factor: 39.397

7.  Oncogenic BRAF regulates oxidative metabolism via PGC1α and MITF.

Authors:  Rizwan Haq; Jonathan Shoag; Pedro Andreu-Perez; Satoru Yokoyama; Hannah Edelman; Glenn C Rowe; Dennie T Frederick; Aeron D Hurley; Abhinav Nellore; Andrew L Kung; Jennifer A Wargo; Jun S Song; David E Fisher; Zolt Arany; Hans R Widlund
Journal:  Cancer Cell       Date:  2013-03-07       Impact factor: 31.743

8.  Pharmacologic suppression of MITF expression via HDAC inhibitors in the melanocyte lineage.

Authors:  Satoru Yokoyama; Erez Feige; Laura L Poling; Carmit Levy; Hans R Widlund; Mehdi Khaled; Andrew L Kung; David E Fisher
Journal:  Pigment Cell Melanoma Res       Date:  2008-06-27       Impact factor: 4.693

9.  MGMT promoter methylation is associated with temozolomide response and prolonged progression-free survival in disseminated cutaneous melanoma.

Authors:  Rainer Tuominen; Rosalyn Jewell; Joost J van den Oord; Pascal Wolter; Ulrika Stierner; Christer Lindholm; Carolina Hertzman Johansson; Diana Lindén; Hemming Johansson; Marianne Frostvik Stolt; Christy Walker; Helen Snowden; Julia Newton-Bishop; Johan Hansson; Suzanne Egyházi Brage
Journal:  Int J Cancer       Date:  2014-11-24       Impact factor: 7.396

10.  A melanocyte lineage program confers resistance to MAP kinase pathway inhibition.

Authors:  Cory M Johannessen; Laura A Johnson; Federica Piccioni; Aisha Townes; Dennie T Frederick; Melanie K Donahue; Rajiv Narayan; Keith T Flaherty; Jennifer A Wargo; David E Root; Levi A Garraway
Journal:  Nature       Date:  2013-11-03       Impact factor: 49.962
  10 in total
  7 in total

Review 1.  The role of histone deacetylase 3 in breast cancer.

Authors:  Rezgar Rahbari; Yousef Rasmi; Mohammad Hassan Khadem-Ansari; Mohammad Abdi
Journal:  Med Oncol       Date:  2022-05-17       Impact factor: 3.064

Review 2.  Signal pathways of melanoma and targeted therapy.

Authors:  Weinan Guo; Huina Wang; Chunying Li
Journal:  Signal Transduct Target Ther       Date:  2021-12-20

3.  A novel endoplasmic reticulum stress-related lncRNA prognostic risk model for cutaneous melanoma.

Authors:  An-An Li; Fan Li; Min Lan; Yu Zhang; Dong Xie; Mei-Ying Yan
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-10       Impact factor: 4.322

Review 4.  Ultraviolet Radiation and Melanomagenesis: From Mechanism to Immunotherapy.

Authors:  Xiaoying Sun; Na Zhang; Chengqian Yin; Bo Zhu; Xin Li
Journal:  Front Oncol       Date:  2020-07-02       Impact factor: 6.244

5.  The Construction and Comprehensive Analysis of ceRNA Networks and Tumor-Infiltrating Immune Cells in Bone Metastatic Melanoma.

Authors:  Runzhi Huang; Zhiwei Zeng; Guangyu Li; Dianwen Song; Penghui Yan; Huabin Yin; Peng Hu; Xiaolong Zhu; Ruizhi Chang; Xu Zhang; Jie Zhang; Tong Meng; Zongqiang Huang
Journal:  Front Genet       Date:  2019-09-25       Impact factor: 4.599

6.  Skin cutaneous melanoma properties of immune-related lncRNAs identifying potential prognostic biomarkers.

Authors:  Yutong Ma; Ning Wang; Shude Yang
Journal:  Aging (Albany NY)       Date:  2022-03-31       Impact factor: 5.682

7.  Down-regulated HDAC3 elevates microRNA-495-3p to restrain epithelial-mesenchymal transition and oncogenicity of melanoma cells via reducing TRAF5.

Authors:  Yanbo Ma; Jincheng Duan; Xiuyan Hao
Journal:  J Cell Mol Med       Date:  2020-10-13       Impact factor: 5.295
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.